[1]
|
Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J.M., Buqué, A., Senovilla, L., Baracco, E.E., Bloy, N., Castoldi, F., Abas-tado, J.P., Agostinis, P., et al. (2014) Classification of Current Anticancer Immunotherapies. Oncotarget, 5, 12472- 12508. https://doi.org/10.18632/oncotarget.2998
|
[2]
|
Fang, Z., Han, H. and Liang, L. (2019) Progression in Chi-meric Antigen Receptor T (CAR-T) Cell Therapy of Solid Tumors: A Review. Chinese Journal of Cellular and Molecu-lar Immunology, 35, 944-948.
|
[3]
|
Krishnamurthy, A. and Jimeno, A. (2018) Bispecific Antibodies for Cancer Thera-py: A Review. Pharmacology & Therapeutics, 185, 122-134. https://doi.org/10.1016/j.pharmthera.2017.12.002
|
[4]
|
Li, X., Shao, C., Shi, Y. and Han, W. (2018) Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy. Journal of Hematology & Oncology, 11, 31. https://doi.org/10.1186/s13045-018-0578-4
|
[5]
|
Weinmann, S.C. and Pisetsky, D.S. (2019) Mechanisms of Immune-Related Adverse Events during the Treatment of Cancer with Immune Checkpoint Inhibitors. Rheumatology (Oxford), 58, vii59-vii67.
https://doi.org/10.1093/rheumatology/kez308
|
[6]
|
Zhao, Y., Yang, W., Huang, Y., Cui, R., Li, X. and Li, B. (2018) Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. Cellular Physiology and Biochemistry, 47, 721-734. https://doi.org/10.1159/000490025
|
[7]
|
Postow, M.A., Callahan, M.K. and Wolchok, J.D. (2015) Im-mune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 33, 1974-1982. https://doi.org/10.1200/JCO.2014.59.4358
|
[8]
|
Burugu, S., Gao, D., Leung, S., Chia, S.K. and Nielsen, T.O. (2017) LAG-3+ Tumor Infiltrating Lymphocytes in Breast Cancer: Clinical Correlates and Association with PD-1/PD-L1+ Tumors. Annals of Oncology, 28, 2977-2984.
https://doi.org/10.1093/annonc/mdx557
|
[9]
|
Huard, B., Prigent, P., Tournier, M., Bruniquel, D. and Triebel, F. (1995) CD4/Major Histocompatibility Complex Class II Interaction Analyzed with CD4- and Lymphocyte Activation Gene-3 (LAG-3)-Ig Fusion Proteins. European Journal of Immunology, 25, 2718-2721. https://doi.org/10.1002/eji.1830250949
|
[10]
|
Dijkstra, J.M., Somamoto, T., Moore, L., Hordvik, I., Ototake, M. and Fischer, U. (2006) Identification and Characterization of a Second CD4-Like Gene in Teleost Fish. Molecular Immunol-ogy, 43, 410-419.
https://doi.org/10.1016/j.molimm.2005.03.005
|
[11]
|
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E. and Hercend, T. (1990) LAG-3, a Novel Lymphocyte Activation Gene Closely Re-lated to CD4. Journal of Experimental Medicine, 171, 1393-1405. https://doi.org/10.1084/jem.171.5.1393
|
[12]
|
Sierro, S., Romero, P. and Speiser, D.E. (2011) The CD4-Like Mole-cule LAG-3, Biology and Therapeutic Applications. Expert Opinion on Therapeutic Targets, 15, 91-101. https://doi.org/10.1517/14712598.2011.540563
|
[13]
|
Workman, C.J., Dugger, K.J. and Vignali, D.A. (2002) Cut-ting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3. The Journal of Immunology, 169, 5392-5395.
https://doi.org/10.4049/jimmunol.169.10.5392
|
[14]
|
Goldberg, M.V. and Drake, C.G. (2011) LAG-3 in Cancer Immunotherapy. Current Topics in Microbiology and Immunology, 344, 269-278. https://doi.org/10.1007/82_2010_114
|
[15]
|
Iouzalen, N. andreae, S., Hannier, S. and Triebel, F. (2001) LAP, a Lymphocyte Activation Gene-3 (LAG-3)-Associated Protein That Binds to a Repeated EP Motif in the Intracellular Re-gion of LAG-3, May Participate in the Down-Regulation of the CD3/TCR Activation Pathway. European Journal of Immunology, 31, 2885-2891.
https://doi.org/10.1002/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2
|
[16]
|
Li, N., Wang, Y., Forbes, K., Vignali, K.M., Heale, B.S., Saftig, P., Hartmann, D., Black, R.A., Rossi, J.J., Blobel, C.P., et al. (2007) Metalloproteases Regulate T-Cell Proliferation and Effector Function via LAG-3. EMBO Journal, 26, 494-504. https://doi.org/10.1038/sj.emboj.7601520
|
[17]
|
Demeure, C.E., Wolfers, J., Martin-Garcia, N., Gaulard, P. and Triebel, F. (2001) T Lymphocytes Infiltrating Various Tumour Types Express the MHC Class II Ligand Lymphocyte Activation Gene-3 (LAG-3): Role of LAG-3/MHC Class II Interactions in Cell-Cell Contacts. European Journal of Cancer, 37, 1709-1718.
https://doi.org/10.1016/S0959-8049(01)00184-8
|
[18]
|
Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., El-Tayar, N., Maigret, B., Dréano, M. and Triebel, F. (1997) Characterization of the Major Histocompatibility Complex Class II Binding Site on LAG-3 Protein. Proceedings of the National Academy of Sciences of the United States of America, 94, 5744-5749.
https://doi.org/10.1073/pnas.94.11.5744
|
[19]
|
Kouo, T., Huang, L., Pucsek, A., Cao, M., Solt, S., Armstrong, T. and Jaffee, E. (2015) Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunology Research, 3, 412-423. https://doi.org/10.1158/2326-6066.CIR-14-0150
|
[20]
|
Dumic, J., Dabelic, S. and Flogel, M. (2006) Galectin-3: An Open-Ended Story. Biochimica et Biophysica Acta, 1760, 616-635. https://doi.org/10.1016/j.bbagen.2005.12.020
|
[21]
|
Mao, X., Ou, M.T., Karuppagounder, S.S., Kam, T.I., Yin, X., Xiong, Y., Ge, P., Umanah, G.E., Brahmachari, S., Shin, J.H., et al. (2016) Pathological α-Synuclein Transmission Initi-ated by Binding Lymphocyte-Activation Gene 3. Science, 353, aah3374. https://doi.org/10.1126/science.aah3374
|
[22]
|
Visan, I. (2019) New Ligand for LAG-3. Nature Immunology, 20, Article No. 111.
https://doi.org/10.1038/s41590-018-0307-8
|
[23]
|
Wang, J., Sanmamed, M.F., Datar, I., Su, T.T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) Fibrinogen-Like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell, 176, 334-347e312.
https://doi.org/10.1016/j.cell.2018.11.010
|
[24]
|
Goldberg, M.V. and Drake, C.G. (2011) LAG-3 in Cancer Immu-notherapy. Current Topics in Microbiology and Immunology, 344, 269-278. https://doi.org/10.1007/82_2010_114
|
[25]
|
马成龙, 沈冬, 孙晓, 关乃富, 孙岳军, 戚春建. LAG-3在非小细胞肺癌细胞中的异位表达及其临床意义[J]. 中国医刊, 2019, 54(9): 1005-1008.
|
[26]
|
黄维, 张庆娟, 刘柯, 徐茜, 周美英. 非小细胞肺癌中免疫检查点表达与临床特征及预后的关系分析[J]. 癌症进展, 2019, 17(5): 571-574.
|
[27]
|
江露, 吴昌平, 徐斌, 蒋敬庭. 胃癌患者血清中可溶性LAG-3分子的水平及意义[J]. 临床检验杂志, 2014, 32(1): 38-40.
|
[28]
|
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., et al. (2010) Tumor-Infiltrating NY-ESO-1-Specific CD8+ T Cells Are Negatively Regulated by LAG-3 and PD-1 in Human Ovarian Cancer. Proceedings of the National Academy of Sciences, 107, 7875-7880. https://doi.org/10.1073/pnas.1003345107
|
[29]
|
Okazaki, T., Okazaki, I.M., Wang, J., et al. (2011) PD-1 and LAG-3 Inhibitory Co-Receptors Act Synergistically to Prevent Autoimmunity in Mice. Journal of Experimental Medicine, 208, 395-407.
https://doi.org/10.1084/jem.20100466
|
[30]
|
Maeda, T.K., Sugiura, D., Okazaki, I.M., et al. (2019) Atypical Motifs in the Cytoplasmic Region of the Inhibitory Immune Co-Receptor LAG-3 Inhibit T Cell Activation. Journal of Biological Chemistry, 294, 6017-6026.
https://doi.org/10.1074/jbc.RA119.007455
|
[31]
|
Blackburn, S.D., Shin, H., Haining, W.N., et al. (2009) Coregula-tion of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors during Chronic Viral Infection. Nature Immunology, 10, 29-37. https://doi.org/10.1038/ni.1679
|
[32]
|
Tian, X., Zhang, A., Qiu, C., et al. (2015) The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects. Journal of Immunology, 194, 3873-3882. https://doi.org/10.4049/jimmunol.1402176
|
[33]
|
Phillips, B.L., Mehra, S., Ahsan, M.H., et al. (2015) LAG3 Ex-pression in Active Mycobacterium tuberculosis Infections. The American Journal of Pathology, 185, 820-833. https://doi.org/10.1016/j.ajpath.2014.11.003
|
[34]
|
Butler, N.S., Moebius, J., Pewe, L.L., et al. (2011) Therapeutic Blockade of PD-L1 and LAG-3 Rapidly Clears Established Blood-Stage Plasmodium Infection. Nature Immunology, 13, 188-195. https://doi.org/10.1038/ni.2180
|
[35]
|
Chen, N., Liu, Y., Guo, Y., et al. (2015) Lymphocyte Activation Gene 3 Negatively Regulates the Function of Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells. Journal of Gastroenterology and Hepatology, 30, 1788-1795.
https://doi.org/10.1111/jgh.13017
|
[36]
|
Dong, Y., Li, X., Zhang, L., et al. (2019) CD4+ T Cell Exhaustion Revealed by High PD-1 and LAG-3 Expression and the Loss of Helper T Cell Function in Chronic Hepatitis B. BMC Immunolo-gy, 20, Article No. 27.
https://doi.org/10.1186/s12865-019-0309-9
|
[37]
|
Erickson, J.J., Rogers, M.C., Tollefson, S.J., et al. (2016) Multi-ple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection. The Journal of Immunology, 197, 233-243. https://doi.org/10.4049/jimmunol.1502115
|
[38]
|
Roy, S., Coulon, P.-G., Srivastava, R., et al. (2018) Blockade of LAG-3 Immune Checkpoint Combined with Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-Viral CD8+ T Cells and Protect against Recurrent Ocular Herpes Simplex Infection and Disease. Frontiers in Immunology, 9, Article No. 2922.
https://doi.org/10.3389/fimmu.2018.02922
|
[39]
|
Cook, K.D. and Whitmire, J.K. (2016) LAG-3 Confers a Competi-tive Disadvantage upon Antiviral CD8+ T Cell Responses. The Journal of Immunology, 197, 119-127. https://doi.org/10.4049/jimmunol.1401594
|
[40]
|
Richter, K., Agnellini, P. and Oxenius, A. (2010) On the Role of the Inhibitory Receptor LAG-3 in Acute and Chronic LCMV Infection. International Immunology, 22, 13-23. https://doi.org/10.1093/intimm/dxp107
|
[41]
|
Huang, C.-T., Workman, C.J., Flies, D., et al. (2004) Role of LAG-3 in Regulatory T Cells. Immunity, 21, 503-513.
https://doi.org/10.1016/j.immuni.2004.08.010
|
[42]
|
Li, M.O. and Rudensky, A.Y. (2016) T Cell Receptor Signal-ling in the Control of Regulatory T Cell Differentiation and Function. Nature Reviews Immunology, 16, 220-233. https://doi.org/10.1038/nri.2016.26
|
[43]
|
Zhang, Q., Chikina, M., Szymczak-Workman, A.L., et al. (2017) LAG3 Limits Regulatory T Cell Proliferation and Function in Autoimmune Diabetes. Science Immunology, 2, eaah4569. https://doi.org/10.1126/sciimmunol.aah4569
|
[44]
|
Gagliani, N., Magnani, C.F., Huber, S., et al. (2013) Coexpres-sion of CD49b and LAG-3 Identifies Human and Mouse T Regulatory Type 1 Cells. Nature Medicine, 19, 739-746. https://doi.org/10.1038/nm.3179
|
[45]
|
Okamura, T., Fujio, K., Shibuya, M., et al. (2009) CD4+CD25-LAG3+ Regulatory T Cells Controlled by the Transcription Factor Egr-2. Proceedings of the National Academy of Sciences of the United States of America, 106, 13974- 13979. https://doi.org/10.1073/pnas.0906872106
|
[46]
|
Okamura, T., Sumi-tomo, S., Morita, K., et al. (2015) TGF-β3-Expressing CD4+CD25(-)LAG3+ Regulatory T Cells Control Humoral Im-mune Responses. Nature Communications, 6, Article No. 6329.
https://doi.org/10.1038/ncomms7329
|
[47]
|
Lino, A.C., Dang, V.D., Lampropoulou, V., et al. (2018) LAG-3 Inhib-itory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells. Immunity, 49, 120-133. https://doi.org/10.1016/j.immuni.2018.06.007
|
[48]
|
Ma, C., Sun, X., Shen, D., Sun, Y., Guan, N. and Qi, C. (2020) Ectopic Expression of LAG-3 in Non-Small-Cell Lung Cancer Cells and Its Clinical Significance. Journal of Clinical Laboratory Analysis, 34, e23244.
https://doi.org/10.1002/jcla.23244
|
[49]
|
He, Y., Yu, H., Rozeboom, L., et al. (2017) LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 12, 814-823.
https://doi.org/10.1016/j.jtho.2017.01.019
|
[50]
|
He, Y., Rivard, C.J., Rozeboom, L., Yu, H., Ellison, K., Kowalew-ski, A., Zhou, C. and Hirsch, F.R. (2016) Lymphocyte-Activation Gene-3, an Important Immune Checkpoint in Cancer. Cancer Science, 107, 1193-1197.
https://doi.org/10.1111/cas.12986
|
[51]
|
Vilgelm, A.E., Johnson, D.B. and Richmond, A. (2016) Combinatorial Ap-proach to Cancer Immunotherapy: Strength in Numbers. Journal of Leukocyte Biology, 100, 275-290. https://doi.org/10.1189/jlb.5RI0116-013RR
|